类风湿关节炎利妥昔单抗注册试验的疗效与安全性数据能否外推?来自AIR-PR登记库1984例患者的启示
基于法国多中心前瞻性AIR-PR登记库1984例接受利妥昔单抗(RTX)治疗的真实世界类风湿关节炎(RA)患者,比较符合与不符合三项RTX注册试验入组标准者的12个月治疗反应和严重不良事件。仅9%~12%符合全部入组标准,不符合者12个月EULAR反应率较低(40.3% vs 46.9%,P=0.044),且存在≥1项关键排除标准者严重不良事件风险更高(风险比3.03;95%CI 2.25~4.06;≥3项标准 vs 0项)。作者认为注册试验的疗效与安全性数据可能无法外推至真实世界接受RTX治疗的RA患者。
要点
- 1984例真实世界RA患者中仅9%~12%符合三项RTX注册试验的全部入组标准。
- 不符合入组标准者12个月EULAR反应率较低(40.3% vs 46.9%,P=0.044)。
- 存在≥1项关键排除标准者严重不良事件风险更高(风险比3.03;95%CI 2.25~4.06;≥3项 vs 0项)。
核心结论
- 真实世界RA患者中仅少数符合RTX注册试验入组标准,不符合者治疗反应机会较低且严重不良事件风险较高。
- 作者认为注册试验获得的疗效与安全性数据可能无法外推至真实世界临床实践中接受RTX治疗的RA患者。
研究设计与样本
- 基于法国多中心前瞻性AIR-PR登记库,纳入1984例真实世界接受RTX治疗的RA患者。
- 通过提取三项RTX注册试验的入组标准,比较符合与不符合者的12个月治疗反应及严重不良事件。
- 确定关键入组标准,并按满足关键入组标准数目建模获益-风险比。
主要发现
- 1984例RA患者中仅9%~12%符合全部入组标准。
- 不符合者12个月EULAR反应率低于符合者(40.3% vs 46.9%,P=0.044)。
- 仅20.8%满足关键入组标准。
- 第一年内182例(9.2%)发生严重不良事件,其中70.3%为严重感染。
- 存在≥1项关键排除标准者严重不良事件风险更高(风险比3.03;95%CI 2.25~4.06;≥3项标准 vs 0项)。
关键数值与推荐
- 关键入组标准包括肿胀关节数≥4、压痛关节数≥4、CRP≥15 mg/l及RF阳性。
- 关键排除标准包括年龄>80岁、RA相关系统性疾病、ACR功能分级IV级、除MTX外的DMARD及泼尼松>10 mg/天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether the efficacy and safety data from drug-registration trials can be extrapolated to real-life RA patients receiving RTX. METHODS: The 'AutoImmunity and Rituximab' (AIR-PR) registry is a French multicentre, prospective cohort of RA patients treated with RTX in a real-life setting. We compared treatment responses at 12 months and serious adverse events (AEs) between eligible and non-eligible patients, by retrieving the eligibility criteria of the three rituximab-registration trials. We determined critical eligibility criteria and modelled the benefit-risk ratio according to the number of fulfilled critical eligibility criteria. RESULTS: Among 1984 RA patients, only 9-12% fulfilled all eligibility criteria. Non-eligible patients had fewer EULAR responses at 12 months (40.3% vs 46.9%, P = 0.044). Critical inclusion criteria included swollen joints count ≥4, tender joints count ≥4, CRP ≥15 mg/l and RF positivity. Critical exclusion criteria were age >80 years, RA-associated systemic diseases, ACR functional class IV, DMARD other than MTX and prednisone >10 mg/day. Only 20.8% fulfilled those critical eligibility criteria. During the first year, serious AEs occurred for 182 (9.2%) patients (70.3% serious infections) and patients with ≥1 critical exclusion criterion were at higher risk (hazard ratio 3.03; 95% CI 2.25-4.06; for ≥3 criteria vs 0). The incremental risk-benefit ratio decreased with the number of unmet critical inclusion criteria and of fulfilled exclusion criteria. CONCLUSION: Few real-life RA patients were eligible for the drug-registration trials. Non-eligible patients had lower chance of response, and higher risk of serious AEs. Efficacy and safety data obtained from those trials may not be generalizable to RA patients receiving RTX in real-world clinical practice.
引用
- Nguyen Y, Mariette X, Gottenberg JE, et al. Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry. Rheumatology (Oxford). 2024. PMID: 37725356. doi:10.1093/rheumatology/kead495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。